128 related articles for article (PubMed ID: 38720543)
1. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Neurourol Urodyn; 2024 May; ():. PubMed ID: 38720543
[TBL] [Abstract][Full Text] [Related]
2. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
4. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
Sussman D; Yehoshua A; Kowalski J; Lee W; Kish J; Chaudhari S; Murray B
Int J Clin Pract; 2017 Mar; 71(3-4):. PubMed ID: 28371019
[TBL] [Abstract][Full Text] [Related]
6. Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.
Dmochowski RR; Rovner ES; Kennelly MJ; Newman DK; Abedinzadeh L; Snyder D; Thomas E; Haag-Molkenteller C; Rosenberg MT
BMC Urol; 2023 Apr; 23(1):64. PubMed ID: 37095473
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.
Kennelly M; Wielage R; Shortino D; Thomas E; Mudd PN
Drugs Context; 2022; 11():. PubMed ID: 36303599
[TBL] [Abstract][Full Text] [Related]
8. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada.
Wagg A; Franks B; Ramos B; Berner T
Can Urol Assoc J; 2015; 9(9-10):343-50. PubMed ID: 26644809
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
10. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
11. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
Kato D; Uno S; Van Schyndle J; Fan A; Kimura T
Int J Urol; 2017 Oct; 24(10):757-764. PubMed ID: 28833621
[TBL] [Abstract][Full Text] [Related]
12. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
Yeowell G; Smith P; Nazir J; Hakimi Z; Siddiqui E; Fatoye F
BMJ Open; 2018 Nov; 8(11):e021889. PubMed ID: 30467131
[TBL] [Abstract][Full Text] [Related]
13. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.
He W; Zhang Y; Huang G; Tian Y; Sun Q; Liu X
Low Urin Tract Symptoms; 2023 May; 15(3):80-88. PubMed ID: 36863312
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
16. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.
Johnson TM; Walker D; Lockefeer A; Jiang B; Nimke D; Lozano-Ortega G; Kimura T
Neurourol Urodyn; 2022 Nov; 41(8):1872-1889. PubMed ID: 36098417
[TBL] [Abstract][Full Text] [Related]
17. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
18. Selectivity and Maximum Response of Vibegron and Mirabegron for β
Brucker BM; King J; Mudd PN; McHale K
Curr Ther Res Clin Exp; 2022; 96():100674. PubMed ID: 35693456
[TBL] [Abstract][Full Text] [Related]
19. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis.
Song YS; Lee HY; Park JJ; Kim JH
J Urol; 2021 Jun; 205(6):1595-1604. PubMed ID: 33207141
[TBL] [Abstract][Full Text] [Related]
20. The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan.
Mukai S; Nomi M; Yamada S; Yanagiuchi A; Sengoku A
Low Urin Tract Symptoms; 2021 Oct; 13(4):448-455. PubMed ID: 34032007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]